Transforming atrial fibrillation management by targeting comorbidities and reducing atrial fibrillation burden: the 10th AFNET/EHRA consensus conference

Multi-domain therapy combining stroke prevention, rhythm control, and therapy of concomitant CV conditions: anti-coagulants, anti-arrhythmic drugs (AADs) and atrial fibrillation (AF) ablation with old and new cardiometabolic drugs that can reduce AF risk, AF burden and AF-related complications

Quantitative traits may enable a shift towards risk-driven therapy based on AF phenotypes

Data science and artificial intelligence applied to quantitative phenotypic and genetic features can further improve risk estimation and personalized therapy selection